Call Now

Human Epcr / PROCR Protein (His Tag)

CCCA,CCD41,EPCR

Catalog Number P13320-H08H
Organism Species Human
Host Human Cells
Synonyms CCCA,CCD41,EPCR
Molecular Weight The secreted recombinant human PROCR consists of 203 amino acids and has a predicted molecular mass of 23.4 kDa. The apparent molecular mass of rhPROCR is approximately 37 kDa in SDS-PAGE under reducing conditions due to glycosylation.
predicted N Ser 18
SDS-PAGE
Purity > 97 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the extracellular domain of human PROCR (Q9UNN8) (Met 1-Thr 209), was fused with a polyhistidine tag at the C-terminus.
Bio-activity
Research Area Immunology |Innate Immunity |Coagulation |Coagulation Cascade
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Endothelial protein C receptor (EPCR), also known as activated protein C receptor (APC receptor) or PROCR, is a receptor for Protein C. Protein C plays an important role in many metabolism processes in humans and other animals after activated by binding to Endothelial protein C receptor (EPCR). Because of the EPCR is found primarily on endothelial cells (cells on the inside of blood vessels), activated protein C is found maily near endothelial cells. Protein C is pleiotropic, with two main functions: anticoagulation and cytoprotection. Which function will be performed depend on whether or not protein C remains bind to EPCR after activated. The anticoagulation occurs when it does not. In this case, protein C functions as an anticoagulant by irreversibly proteolytically inactivating Factor Va and Factor VIIIa, turning them into Factor Vi and Factor VIIIi respectively. When still bound to EPCR, activated protein C performs its cytoprotective effects, acting on the effector substrate PAR-1, protease-activated receptor-1. To a degree, APC's anticoagulant properties are independent of its cytoprotective ones, in that expression of one pathway is not affected by the existence of the other. 
Reference
  • Nicolaes GA, et al. (2003). Congenital and acquired activated protein C resistance. Semin Vasc Med. 3 (1): 33-46.
  • Esmon CT. ( 2003). The protein C pathway. Chest 124 (3): 26-32.
  • Mosnier LO, et al. (2007)The cytoprotective protein C pathway. Blood. 109: 3161-72.